journal article·2016-08-31

Reversing Cancer Multidrug Resistance in Xenograft Models via Orchestrating Multiple Actions of Functional Mesoporous Silica Nanoparticles

Debin Yang, Tingfang Wang, Zhigui Su, Lingjing Xue, Ran Mo, Can Zhang

Publisher page

Abstract

A multistimuli responsive drug delivery system (DDS) based on sulfhydryl and amino-cofunctionalized mesoporous silica nanoparticles (SH/NH2-MSNs) has been developed, in which the multifunctional hyaluronic acid (HA) derivatives were grafted onto the SH/NH2-MSNs by disulfide bonds for targeting delivery, controlling drug release and reversing multidrug resistance (MDR). The doxorubicin (Dox) loaded multifunctional HA derivatives modified mesoporous silica nanoparticles (Dox/HHS-MSNs) were enzyme and redox sensitive, which could respond to the intracellular stimuli of hyaluronidase (HAase) and glutathione (GSH) successively and prevent drug leakage before reaching the tumor tissues. The cellular uptake experiments showed that Dox/HHS-MSNs were vulnerable to be endocytosed into the Dox-resistant human breast adenocarcinoma (MCF-7/ADR) cells, efficiently realized the endolysosomal escape and remained in the cytoplasm. Because of orchestrating multiple actions above including active targeting, endolysosomal escape and efficient multilevel drug release, Dox/HHS-MSNs could induce the strongest apoptosis and cytotoxicity of MCF-7/ADR cells. Furthermore, a series of in vivo studies on MCF-7/ADR tumor-bearing xenograft mouse models demonstrated that Dox/HHS-MSNs possessed the enhanced tumor-targeting capacity and the best therapeutic efficacy to reverse cancer MDR.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Proteoglycans and glycosaminoglycans research · Glycosylation and Glycoproteins Research · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, China

Funding

National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities of China · National Basic Research Program of China · 111 Project from the Ministry of Education of China and the State Administration of Foreign Expert Affairs of China · Natural Science Foundation of Jiangsu Province of China

References (57)

Show source-provided references
1. 10.3322/caac.2116610.3322/caac.21166 ↗
2. 10.1038/nrc334210.1038/nrc3342 ↗
3. 10.1038/nrc359910.1038/nrc3599 ↗
4. 10.1016/S0344-0338(96)80099-910.1016/S0344-0338(96)80099-9 ↗
5. 10.2174/13894501179537854010.2174/138945011795378540 ↗
6. 10.1016/j.addr.2013.04.01110.1016/j.addr.2013.04.011 ↗
7. 10.1016/j.addr.2013.09.00110.1016/j.addr.2013.09.001 ↗
8. 10.1038/nrc326410.1038/nrc3264 ↗
9. 10.2217/nnm.10.3510.2217/nnm.10.35 ↗
10. 10.1016/j.jconrel.2014.09.02010.1016/j.jconrel.2014.09.020 ↗
11. 10.1021/nn401079610.1021/nn4010796 ↗
12. 10.1039/C5RA06445G10.1039/C5RA06445G ↗
13. 10.1002/adfm.20130322210.1002/adfm.201303222 ↗
14. 10.1038/ncomms436410.1038/ncomms4364 ↗
15. 10.1002/chem.20130106010.1002/chem.201301060 ↗
16. 10.1021/nl400681f10.1021/nl400681f ↗
17. 10.1016/j.jconrel.2013.06.00310.1016/j.jconrel.2013.06.003 ↗
18. 10.1021/am400470510.1021/am4004705 ↗
19. 10.1038/354291a010.1038/354291a0 ↗
20. 10.1016/S0169-409X(02)00179-510.1016/S0169-409X(02)00179-5 ↗
21. 10.1021/acsami.5b0958510.1021/acsami.5b09585 ↗
22. 10.1039/C5NR05139H10.1039/C5NR05139H ↗
23. 10.1002/adma.20040077110.1002/adma.200400771 ↗
24. 10.1021/ja028650l10.1021/ja028650l ↗
25. 10.1016/j.biomaterials.2012.11.04410.1016/j.biomaterials.2012.11.044 ↗
26. 10.1021/ja312221g10.1021/ja312221g ↗
27. 10.1002/anie.20050181910.1002/anie.200501819 ↗
28. 10.1039/c0cp02959a10.1039/c0cp02959a ↗
29. 10.1021/am403092m10.1021/am403092m ↗
30. 10.1021/acsbiomaterials.5b0050210.1021/acsbiomaterials.5b00502 ↗
31. 10.1021/ja312004m10.1021/ja312004m ↗
32. 10.1002/anie.20100506110.1002/anie.201005061 ↗
33. 10.1021/nn404676w10.1021/nn404676w ↗
34. 10.1021/ja211035w10.1021/ja211035w ↗
35. 10.1038/nrc139110.1038/nrc1391 ↗
36. 10.1078/0171-9335-0039210.1078/0171-9335-00392 ↗
37. 10.1158/1078-0432.CCR-09-047910.1158/1078-0432.CCR-09-0479 ↗
38. 10.1158/0008-5472.CAN-06-146410.1158/0008-5472.CAN-06-1464 ↗
39. 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-110.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1 ↗
40. 10.1111/j.1476-5381.2009.00288.x10.1111/j.1476-5381.2009.00288.x ↗
41. 10.1016/j.ejpb.2013.06.01510.1016/j.ejpb.2013.06.015 ↗
42. 10.1158/1535-7163.MCT-10-088410.1158/1535-7163.MCT-10-0884 ↗
43. 10.1039/c2jm15489g10.1039/c2jm15489g ↗
44. 10.1002/chem.20120203810.1002/chem.201202038 ↗
45. 10.1039/C2NR32145A10.1039/C2NR32145A ↗
46. 10.1021/bc900444310.1021/bc9004443 ↗
47. 10.1038/onc.2012.18310.1038/onc.2012.183 ↗
48. 10.1016/j.ceca.2011.12.00910.1016/j.ceca.2011.12.009 ↗
49. 10.1021/bc200139n10.1021/bc200139n ↗
50. 10.1007/s11095-012-0766-910.1007/s11095-012-0766-9 ↗
51. 10.1016/0003-9861(59)90090-610.1016/0003-9861(59)90090-6 ↗
52. 10.1016/j.micromeso.2009.01.00610.1016/j.micromeso.2009.01.006 ↗
53. 10.1016/j.biomaterials.2013.01.03010.1016/j.biomaterials.2013.01.030 ↗
54. 10.1016/j.ijpharm.2013.01.05810.1016/j.ijpharm.2013.01.058 ↗
55. 10.1021/ac034771810.1021/ac0347718 ↗
56. 10.1016/j.micromeso.2007.11.03010.1016/j.micromeso.2007.11.030 ↗
57. 10.1016/j.addr.2012.09.00710.1016/j.addr.2012.09.007 ↗